tbuckley/cabot-search huggingface dataset:
Hematuria: algorithms for diagnosis. I. Hematuria in the child
Authors: E. D. Brewer
Journal: JAMA (1981)

HEMATURIA, either gross or microscopic, in any patient warrants laboratory investigation. The direction and magnitude of this evaluation is dependent to a large extent on the age and sex of the patient and the presence or absence of a urinary tract infection. For example, hematuria in an otherwise asymptomatic 70-year-old man requires a significantly different evaluation than does hematuria in a 20-year-old woman with symptoms of cystitis or in an 8-year-old child with increased blood pressure. In this two-part series, three algorithms for the evaluation of hematuria are presented. Part 1 addresses the problem of hematuria in the child, and part 2, which will appear next week, deals with hematuria in the adult and hematuria secondary to trauma. <h3>HEMATURIA IN THE CHILD</h3> In children, the laboratory investigation of hematuria begins with a urinalysis and urine culture. Further evaluation depends on the results of these tests. If the child has hematuria
Holes in the Swiss Health Care System
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Metallic Taste
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Small intestine
Authors: N Hudson, A Taha, R Sturrock, R Russell, G Bianchi, Porro Lazzaroni
Journal: Gut (1992)

Nonsteroidal anti -inflammatory drugs (NSAIDs) cause gastroduodenal mucosal injury and ulceration.It is unclear whether damage is potentiated by Helicobacter pylori (H.p) colonisation. 229patients with rheumatoid or osteoarthritis underwent a screening upper gastrointestinal endoscopy to assess gastroduodenal injury.H.p status was determined by a rapid urease test and confirmed by histology.. RESULTS The overall prevalence of gastroduodenal ulceration was 32.3% (24.4% GU, 12.2% DU) and haemorrhagic or non- haemorrhagic erosions 27.5%.Erosions were more prevalent in conjunction with ulceration (37.8% vs 22.5%, p<0.025Chi2 test)The presence of upper abdominal symptoms was not significantly associated with ulceration (ulcers; 45.9% vs no ulcers; 32.9%).The prevalence of H.p colonisation was significantly higher in patients with ulcers 54.0% than patients without 38.7% ( p < 0.05) although mucosal erosions were not more prevalent in patients colonised with H.p (31% vs 24.8%).There were no differences between H.p prevalence in patients with GU (51.7%) or DU (57.1%) and H.p colonisation did not affect the age or sex distribution or symptom status of patients with ulceration.CONCLUSIONS Gastroduodenal ulceration in NSAID users is more prevalent in those colonised with Helicobacter pylori.This is not accounted for solely by an increase in duodenal ulcers and suggests eradication therapy maybe of value in these patients.T166
Update: Vibrio cholerae O1—Western Hemisphere, 1991-1994, and V. cholerae O139—Asia, 1994
Journal: JAMA (1995)

The cholera epidemic caused by Vibrio cholerae O1 that began in January 1991 has continued to spread in Central and South America (Figure 1). In southern Asia, the epidemic caused by the newly recognized strain V. cholerae O139 that began in late 1992 also has continued to spread (Figure 2). This report updates surveillance findings for both epidemics.
Medical society review programs
Authors: H. Hassard
Journal: JAMA (1966)

Many years before Medicare came to pass, the California Medical Association set out to develop a series of disciplinary mechanisms for the medical profession. Self-discipline among professional men and organizations is far more efficient than any sort of "discipline" that could possibly come out of a government bureau. Self-imposed review of medical practice and utilization of health facilities are necessary at all levels; the informed judgments of our peers can often be much harsher than the uninformed judgments from outside bodies. There are four key areas of medical care in which the public expects help from the medical profession: cost, quality, availability, and scope of service. The California medical review programs have been developed carefully over the past few years to provide just that help. CMA has sought to serve as a catalyst in the state-wide development of these programs. One pioneering program, called "Guiding Principles for Physician-Hospital Relationships," was
BOOK REVIEWS
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article BOOK REVIEWS Get access Reasoning and Decision Making in Hematology . Benjamin Djulbegovic ed. New York : Churchill Livingstone , 1992 . 253 pp., illus. $44.95. Reviewed by Eric J. Seifter [J Natl Cancer Inst 85:829–830, 1993] JNCI: Journal of the National Cancer Institute, Volume 86, Issue 3, 2 February 1994, Page 235, https://doi.org/10.1093/jnci/86.3.235-c Published: 02 February 1994
Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patient
Authors: F. Fulfaro, M. R. Valerio, G. Badalamenti, C. Arcara, G. Cicero, C. Intrivici, A. Crosta, C. Sciortino, A. Russo, N. Gebbia
Journal: Journal of Clinical Oncology (2004)

704 Background: Paclitaxel-Doxorubicin combination chemotherapy is highly active in metastatic breast cancer patients (pts) but may be cardiotoxic in a small percentage of cases. PLD is a new formulation of Doxorubicin with significant reduced cardiac toxicity and for this reason PLD can be given safe in elderly patients with cardiac risk factors or in younger patients with prior exposure to anthracycline-containing regimens. The main side effect of PLD is Hand-Foot syndrome but when given in intervals not below 4 weeks and with a dose intensity not exceeding 10 mg/sqm per week, this side effects is clearly reduced. Methods: : We carried out a phase 2 study to verify the activity of P 70 mg/sm weekly day 1–8-15 and PLD 30 mg/mq every four weeks. Inclusion Criteria were: age <75, Performance Status (PS)<=2, normal kidney and liver function, absence of brain symptomatic metastases, adjuvant chemotherapy with anthracyclines (relapse free survival>12months) or patients with LVEF beetween 40–50%, informed consent. Results: Out of the 11 patients so far included, 9 were evaluable for toxicity and response. Five patients (55.5%) showed a response including 4 PR and 1 CR, 1 patients (11.1 %) obtained SD and 2 pts (33.3%) progressed. Median time to progression and median survival have to be reached. Haematological side effects were: Neutropenia G1–2 in 4 pts (44.4%), thrombocytopenia G1–2 in 3 pts (33.3%). The non-haematological side effects were mild with the total absence of grade 3–4 toxicities. Only 3 patients (33.3%) experienced grade 2 nausea and stomatitis. G1–2 peripheral sensory neuropathy was seen in 1 pt (11.1%). Hand-Foot syndrome G1–2 occurred in 2 pts (22.2%). Conclusions: The treatment with weekly Paclitaxel and PLD with this schedule appears to be a well tolerated therapy with an interesting activity in this subset of patients. No significant financial relationships to disclose.
IGF-Child-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy.
Authors: Yehia I. Abugabal, Manal Hassan, Lianchun Xiao, Jeffrey Morris, Roberto Carmagnani Pestana, Reham Abdel-Wahab, Rikita Hatia, Ping Chang, Lauren Girard, Asif Rashid, George Bhawana, Kanwal Pratap Singh Raghav, Ahmed Abdelhakeem, Robert A. Wolff, Hesham M. Amin, Ahmed Omar Kaseb
Journal: Journal of Clinical Oncology (2019)

223 Background: Sorafenib is the first systemic therapy approved for advanced HCC treatment; with no accurate tool available to help predict survival and treatment outcome and to guide therapy decisions. Our novel blood-based IGF-Child-Pugh (CP) score comprises levels of IGF-1, bilirubin, INR, and albumin. IGF-CP score significantly improved the prediction of HCC survival in our recently published studies. The current prospective study aimed to compare the overall survival (OS) and progression free survival (PFS) of 101 patients with CP-A HCC treated with sorafenib whose score is reclassified as IGF-A (AA) to that of patients whose score is reclassified as IGF-B/C (AB/AC). Methods: Between 2014 and 2018, after the approval of the institutional review boards and signing written informed consent, a total of 101 patients with HCC, CP-A were prospectively enrolled and started on sorafenib and followed until progression or death. Results: Sixty-three patients were evaluable. Patients who were reclassified by the IGF-CTP scoring system were better stratified by their new risk groups. Forty-two of patients were classified as IGF-CTP-A and had median PFS of 4.87 months (95% CI=2.3 to 6.84), and median OS of 15.43 (95% CI = 12.04 to 31.18 months), whereas 21 patients were reclassified as intermediate risk (IGF-CTP-B) and had significantly shorter OS of 7.6 months (p-value&lt;0.0001) and shorter PFS of 2.86 months (p-value=0.0021). Conclusions: The results of this study confirms our biologically driven hypothesis that: among HCC patients with “old CP-A” class treated with sorafenib, some will be reclassified as “new CP-B/C” will have poorer prognosis in terms of shorter OS and PFS. Thus, our study provides an objective non-invasive strategy to better predict the outcome in HCC patients undergoing systemic therapy. Future validation of our IGF score may lead to adopting it as a stratification tool in trials to predict HCC outcome and guide therapy decision in routine practice. [Table: see text]
Pritikin vs AHA diet: no difference for peripheral vascular disease
Authors: M. Korcok
Journal: JAMA (1981)

Among the claims being made on behalf of the Pritikin program, which combines a high-fiber, lowfat diet with exercise, is that it can produce dramatic regressions of atheroma in persons with peripheral vascular disease. Such claims have occasionally been spiced up with stories of octogenarians entering and winning sprints and road races and leaving behind all symptoms of angina, congestive heart failure, and claudication. But a recent study carried out at the University of Alberta in Edmonton and reported at the meeting of the Royal College of Physicians and Surgeons in Toronto has shown that a group of Pritikin regimen adherents achieved no greater health benefit for their efforts than did disciples of the more moderate American Heart Association (AHA) diet combined with exercise. In particular, there was no improvement of blood flow in their limbs. Furthermore, because of the restrictions on fat and protein intake, there is some concern
FOG-1 Requires NuRD to Promote Hematopoiesis and Maintain Lineage Fidelity within the Megakaryocytic–Erythroid Compartment.
Authors: Gregory D Gregory, Annarita Miccio, Alexey Bersenev, Yuhuan Wang, Wei Hong, Zhe Zhang, Mortimer Poncz, Wei Tong, Gerd A Blobel
Journal: Blood (2009)
Acellular pertussis vaccines available soon for fourth, fifth doses of DTP immunization
Authors: C. Marwick
Journal: JAMA (1992)

THE LONG-AWAITED acellular pertussis vaccines are about to become available for use in the fourth and fifth doses of the childhood diphtheria-tetanus-pertussis (DTP) immunization schedule. Although there is no move at present to incorporate the acellular form of the vaccine into the first three doses of the routine childhood DTP immunization schedule, the coming licensure of these vaccines marks the first step toward their eventual availability for the entire DTP schedule. Studies are being done by manufacturers and the National Institutes of Health, Bethesda, Md, to test the safety and efficacy of these acellular agents when used in the first three doses. In the meantime, an advisory committee of the Food and Drug Administration, Rockville, Md, having heard evidence from two manufacturers— Lederle Laboratories, Wayne, NJ, and Connaught Laboratories, Swiftwater, Pa—that the acellular vaccines are at least as immunogenic as the whole-cell product and have fewer untoward reactions, recommended fourth
Abstract 1465: Cardiomyocyte Hypertrophy Induces O-linked-β-N-acetylglucosamine Modification of PGC-1α and Augments its Transcriptional Activity
Authors: Heberty T Facundo, Charles R Pratridge, Sumanth D Prabhu, Steven P Jones
Journal: Circulation (2008)

Background and Hypothesis: PGC-1α (peroxisome proliferator activated receptor-gamma coactivator-1α) coordinately regulates fatty acid metabolism. The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal. We hypothesized that metabolic changes during cardiomyocyte hypertrophy might involve interaction between glycolysis and fatty acid metabolism, specifically via O-GlcNAc modification of PGC-1α. Methods and Results: Mechanical stretch (24 h at 4%; Flexercell FX-4000) in neonatal rat cardiomyocytes (n &gt; 4/group) induced a significant (p&lt;0.05) increase (113 ± 35% over No Stretch) in ANP mRNA, confirming induction of hypertrophy. Mechanical stretch significantly augmented (p&lt;0.001; n = 5) global O-GlcNAcylation of several proteins, which was completely reversed by adenoviral overexpression of the deglycosylating enzyme (O-GlcNAcase). Mechanical stretch also augmented mRNA levels of O-GlcNAc transferase (OGT: adds O-GlcNAc to proteins) and glutamine:fructose aminotransferase (GFAT: rate-limiting step for the O-GlcNAc sugar donor), further indicating recruitment of O-GlcNAc signaling. Immunoprecipitation identified PGC-1α as an O-GlcNAc target in this cardiomyocyte hypertrophy model. Real-time (q)-PCR revealed that O-GlcNAc modification of PGC-1α correlated with elevated mRNA levels (n=4/group) of MCAD and COXIV-5b, implying transcriptional activation of PGC-1α. Conclusions: Cardiomyocyte hypertrophy induces O-GlcNAcylation of PGC-1α and represents a surprising and novel potential regulatory interaction between glycolytic and fatty acid metabolism. This research has received full or partial funding support from the American Heart Association, AHA National Center.
Facteurs associés à un saignement retardé après la résection de gros polypes colorectaux non pédiculés
Journal: Endoscopy (2018)

Les saignements retardés dans les suites des mucosectomies de polypes supérieurs à 2 cm surviennent dans 2,7 à 7,2 %. Les facteurs de risques associés à un saignement retardé, identifiés dans la littérature, sont l’âge, l’existence de comorbidité, l’aspirine, la localisation colique droite, la taille de la lésion, la survenue d’une hémorragie immédiate, et l’utilisation d’un bistouri électrique non géré par un microprocesseur. Le but de cette étude prospective était d’évaluer les facteurs influençant le risque d’hémorragie retardée, notamment l’analyse du site de résection.
BERIBERI IN THE UNITED STATES.
Journal: JAMA (1907)

There is probably little danger of the extensive spread in most portions of our country of any introduced tropical disease. Yellow fever, perhaps, might be considered an exception, but we know better how to protect ourselves from that than was formerly the case, and the late experience in New Orleans shows that even if introduced it can be controlled by an efficient health administration. The habits of our people, as a rule, are not such as to favor the virulent spread of such disorders as plague, leprosy, etc., though constant vigilance against their invasion is certainly advisable. Where large numbers of orientals congregate, however, there is a possibility that they may bring unwelcome diseases which may get out of hand in such communities if overlooked or neglected. Thus, it is not entirely satisfactory to hear of an outbreak of beriberi among Japanese laborers in Nebraska, and if this disease is
Auricular Fibrillation.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Illness Memoir
Authors: Katherine Gundling
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetic epidemiology of HbS in Oman: Multicentric origin for the βS gene
Authors: S Daar, H M Hussain, D Gravell, R L Nagel, R Krishnamoorthy
Journal: American Journal of Hematology (2000)

On the basis of a sample of 117 chromosomes, we have demonstrated the multicentric origin of the sickle mutation in Northern Oman. Three major haplotypes coexist: 52.1% Benin (typical and atypicals), 26.7% Arab-India, and 21.4% Bantu. These haplotypes are not autochthonous to Oman but originated elsewhere and arrived in Oman by gene flow. The distribution of haplotypes is in excellent agreement with the historical record, which establishes clear ancient contacts between Oman and sub-Sahara west Africa and explains the presence of the Benin haplotype; contacts with Iraq, Iran, present-day Pakistan, and India explain the presence of the Arab-India haplotype. More recent contacts with East Africa (Zanzibar/Mombasa) explain the presence of the Bantu haplotype. The pattern of the Arab-India haplotype in the populations of the Arabian peninsula reinforces the hypothesis that this particular mutation originated in the Harappa culture or in a nearby population and in addition reveals that the Sassanian Empire might have been the vehicle by which this Indo-European sickle mutation migrated (gene flow) to the present-day Arabian peninsula, including Oman.
Queries and Minor Notes: Then and Now
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal